WorldCare Clinical, LLC (WCC) has introduced a new service aimed at enabling efficient capture and analysis of both standard tumor assessment, such as RECIST (Response Evaluation Criteria in Solid Tumors), and the newer immune-related response criteria (irRC), simultaneously. The new method, developed in collaboration with academic researchers, has been validated and is being used to evaluate new immune-related treatments.
The new service was designed for sponsors developing immunotherapeutic agents who want to analyze performance using irRC, but also want to capture RECIST responses until the newer irRC becomes more established.
“Employing a combined approach to tumor assessment allows for time savings when performing the imaging interpretation, resulting in a significant cost savings to the sponsor,” said Richard Walovitch, Ph.D., president of WorldCare Clinical. “Using our combination CRF, we’re able to programmatically calculate the response using the criteria of both methods.”